• Eupraxia Pharmaceuticals reached its 120-patient enrollment target for the Phase 2b RESOLVE trial of EP-104GI for eosinophilic esophagitis on October 12, 2026.
• Interim results are expected in December 2026, covering symptoms, tissue findings and safety.
• Safety observations to date indicate EP-104GI has been generally well tolerated, with no treatment-related serious adverse events across both trial phases.
• Periodic data reviews indicate no enrollment increase is needed to meet the study’s statistical objectives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150800PRIMZONEFULLFEED9846223) on October 15, 2026, and is solely responsible for the information contained therein.